Introduction
I have written about companies working on research and development of cell therapies as the next frontier in cancer treatment. Current approved treatments such as CAR Ts are autologous treatments and require complex personalised manufacturing and can't be scaled up, which, in turn, drive up costs and limit patient's accessibility. It has been well documented that the approved CAR Ts are facing manufacturing issues and underperformed commercially.
To circumvent this, companies such as Atara Biotherapeutics (ATRA) and Allogene Therapeutics (ALLO) are working on allogeneic T cell therapies, which are